PTC Therapeutics Inc. | Ownership
Companies that own PTC Therapeutics Inc.
RTW Investments LP
4,073,690
8.11%
-64,270
9.77%
06/30/2018
BlackRock Fund Advisors
3,193,521
6.36%
274,477
0.01%
06/30/2018
The Vanguard Group, Inc.
3,107,388
6.19%
215,768
0%
06/30/2018
SSgA Funds Management, Inc.
2,516,928
5.01%
355,522
0.01%
06/30/2018
Scopia Capital Management LP
2,303,341
4.59%
-3,610,711
1.65%
06/30/2018
venBio Select Advisor LLC
2,294,877
4.57%
2,294,877
3.27%
06/30/2018
D. E. Shaw & Co. LP
2,274,463
4.53%
-112,857
0.15%
07/17/2018
Tavistock Life Sciences Co. (Investment Management)
1,900,000
3.78%
-787,330
5.44%
06/30/2018
Marshall Wace North America LP
1,709,974
3.41%
1,048,803
0.38%
06/30/2018
Great Point Partners LLC
1,568,500
3.12%
28,678
8.98%
06/30/2018
| Address |
100 Corporate Court
South Plainfield New Jersey 07080
United States
|
|
Employees
|
- |
| Website |
http://www.ptcbio.com |
| Updated |
07/08/2019 |
| PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel medicines using its expertise in RNA biology. The company's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. It is focused on developing treatments to fundamentally change the lives of patients living with rare genetic disorders. |
